Feasibility Trial of Prolonged versus Single-Dose Challenge in Penicillin Allergy
Conducting a double-blind, placebo-controlled randomized trial of single-dose versus multidose oral amoxicillin challenge was feasible. A fully powered efficacy trial is needed to assess between-group differences in immune-mediated adverse events. (Funded by Austin Health and others; trial registration: ANZCTR - ACTRN12623001242617, registered on November 30, 2023.).
Authors
- Elise Mitri (ORCID: https://orcid.org/0000-0002-1250-2847)
- M. R. Rose
- Michelle Goh (ORCID: https://orcid.org/0000-0001-8063-8482)
- Amy C. Legg
- Sara Vogrin (ORCID: https://orcid.org/0000-0002-1597-9421)
- Jason A. Trubiano (ORCID: https://orcid.org/0000-0002-5111-6367)
- Richard Sullivan
- Irvin Ng (ORCID: https://orcid.org/0000-0002-1357-4666)
- Kyra Chua (ORCID: https://orcid.org/0000-0001-8826-7137)
- Kerryn McInnes
- Gordon Reynolds
- Daniel G Lapirow
- Ana Maria Copaescu
- Michael Lane
- Fiona James
- Natasha E. Holmes
- Joseph De Luca
- Rebecca Hall
Institutions
- The University of Queensland (AU)
- Royal Brisbane and Women's Hospital (AU)
- Peter MacCallum Cancer Centre (AU)
- McGill University Health Centre (CA)
- ENT and Allergy (US)
- Peter Doherty Institute (AU)
- St George Hospital (AU)
- Austin Health (AU)
- McGill University (CA)
Publication Details
- Journal
- NEJM Evidence
- Published
- 2026-02-24
- DOI
- https://doi.org/10.1056/evidoa2500038
- Citations
- 1
- Primary Topic
- Drug-Induced Adverse Reactions
- Type
- article
- Field-Weighted Citation Impact
- 32.57